Correction to: Potential cost-savings from the use of the biosimilars filgrastim, infliximab and insulin glargine in Canada: a retrospective analysis
BMC Health Serv Res
.
2019 Dec 18;19(1):972.
doi: 10.1186/s12913-019-4829-z.
Authors
Kerry Mansell
1
,
Hishaam Bhimji
1
,
Dean Eurich
2
,
Holly Mansell
1
Affiliations
1
College of Pharmacy and Nutrition, University of Saskatchewan, Saskatoon, SK, S7N 2Z4, Canada.
2
School of Public Health, University of Alberta, Edmonton, AB, T6G 2E1, Canada.
PMID:
31849317
PMCID:
PMC6918652
DOI:
10.1186/s12913-019-4829-z
Abstract
In the original publication of this article [1], there is a mistake in the Fig. 2a, 2b, and 2c.
Publication types
Published Erratum